Genetically modified models represent one of the most powerful methods of functional gene analysis. The ability to introduce specific mutations into the genome enables models of human disease to be generated, facilitating insights into the pathophysiology of disease and providing a model with which therapeutic strategies and diagnostic tools can be optimized.
The research activity of the group is focused on the development of novel methodologies for the generation of genetically modified models. The aims being to improve the reliability of the technology and to reduce the animal cost of research involving genetically modified models.
Projects within the group are currently addressing:
- the use of CRISPR/Cas9 site specific nucleases in stem cells and embryos
- the role of PRDM9 in determining the positioning of meiotic recombination events.
- integrase enzymes for the efficient unidirectional insertion of genetic material within specific chromosomal sites.
- multiplexing recombination systems for the development of multipurpose alleles
Our group provides groups within Oxford University access to transgenic technologies both on a fee-for-service type arrangement and on a collaborative basis. Technologies offered include nuclease mediated genome engineering, embryo microinjection, human iPS cell and mouse embryonic stem cell manipulation, Knock-out/-in construct design and in vivo shRNA mediated gene Knock-down. In addition, embryo rederivation and cryopreservation services are offered to facilitate the management, transfer and security of genetically modified strains.
Research within the group is currently funded by the Wellcome Trust and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)
Genome editing, Site-specific nuclease, Transgenic, Knock-out, Functional Gene Analysis, Knock-down, Genetically Modified Model, CRISPR-Cas9